Immune checkpoint inhibitors for urothelial carcinoma: the current landscape
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thoma...
Author: VJOncology
Added: 02/09/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts